**Meeting with EFPIA**

**Meeting date and place**
Meeting held on 11/10/2018 15:00 in Charlemagne

**Participating organisation(s) & representative(s)**

<table>
<thead>
<tr>
<th>Participant</th>
<th>European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requester</td>
<td>European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)</td>
</tr>
<tr>
<td>Notetaker</td>
<td>European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)</td>
</tr>
</tbody>
</table>

**Main issues discussed**

Upon EFPIA request, DG Trade received [Art.4.1(b)] and his industry colleagues on EU-US regulatory cooperation prospects in the context of the Executive Working Group set up by EU and US leaders on 25 July 2018.

[Art.4.1(b)] gave an overview of the state of play as regards the implementation of the 25 July declaration in the regulatory field and potential avenues for work in the regulatory sector, inviting industry to identify priorities for cooperation.

EFPIA flagged the importance of EU-US cooperation on “advanced testing of medical products” and ‘good clinical practices’ which are subject to inspections, similar to GMP for pharma; [Art.4.1(a)] and this would be an area for cooperation. The importance of 3D printing and artificial intelligence was also flagged. We asked for their written input.

**Directorate or unit**
TRADE E/1

**Internal participants**

<table>
<thead>
<tr>
<th>Participant</th>
<th>TRADE E/1</th>
<th>TRADE E/1 @ec.europa.eu</th>
</tr>
</thead>
</table>

**Author(s) of minutes**

[Art.4.1(b)]

**Validator and validation date**

[Art.4.1(b)] validated the minutes on 17/10/2018 09:04